Recuperating Biopharmaceutical Aspects of Amphotericin B and Paromomycin Using a Chitosan Functionalized Nanocarrier via Oral Route for Enhanced Anti-leishmanial Activity.


Journal

Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359

Informations de publication

Date de publication:
2020
Historique:
received: 18 06 2020
accepted: 09 09 2020
entrez: 12 11 2020
pubmed: 13 11 2020
medline: 22 6 2021
Statut: epublish

Résumé

The design and development of new pharmaceutical formulations for the existing anti-leishmanial is a new strategic alternate to improve efficacy and safety rather than new drug discovery. Herein hybrid solid lipid nanoparticles (SLN) have been engineered to direct the oral delivery of two anti-leishmanial drugs amphotericin B (AmB) and paromomycin (PM). The combinatorial nanocarriers consist of conventional SLN, antileishmanial drugs (AmB and PM) which have been functionalized with chitosan (Cs) grafted onto the external surface. The Cs-SLN have the mean particle size of 373.9 ± 1.41 nm, polydispersity index (PDI) of 0.342 ± 0.02 and the entrapment efficiency for AmB and PM was found to be 95.20 ± 3.19% and 89.45 ± 6.86 %, respectively. Characterization of SLN was performed by scanning electron microscopy and transmission electron microscopy. Complete internalization of the formulation was observed in Caco-2 cells. Cs-SLN has shown a controlled and slow drug release profile over a period of 72 h and was stable at gastrointestinal fluids, confirmed by simulated gastro-intestinal fluids study. Cs coating enhanced the mucoadhesive property of Cs-SLN.

Identifiants

pubmed: 33178626
doi: 10.3389/fcimb.2020.570573
pmc: PMC7593694
doi:

Substances chimiques

Biological Products 0
Drug Carriers 0
Paromomycin 61JJC8N5ZK
Amphotericin B 7XU7A7DROE
Chitosan 9012-76-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

570573

Informations de copyright

Copyright © 2020 Parvez, Yadagiri, Karole, Singh, Verma, Sundar and Mudavath.

Références

Br J Clin Pharmacol. 1983 Jul;16(1):106-8
pubmed: 6882617
Eur J Pharm Biopharm. 2009 Feb;71(2):181-9
pubmed: 18940256
Nat Rev Microbiol. 2007 Nov;5(11):873-82
pubmed: 17938629
Food Sci Biotechnol. 2017 Dec 13;27(2):441-450
pubmed: 30263768
Drug Deliv Transl Res. 2020 Feb;10(1):34-42
pubmed: 31240624
Int J Pharm. 2015 Nov 30;495(2):719-27
pubmed: 26410757
Expert Opin Drug Deliv. 2014 May;11(5):633-46
pubmed: 24606222
J Nanobiotechnology. 2015 Jul 10;13:47
pubmed: 26156035
AAPS PharmSciTech. 2018 Oct;19(7):3152-3164
pubmed: 30136175
Parasitol Res. 2018 Jul;117(7):2323-2326
pubmed: 29717371
Mol Pharm. 2019 Nov 4;16(11):4519-4529
pubmed: 31509418
J Control Release. 2017 Mar 10;249:150-161
pubmed: 28153762
Drug Deliv Transl Res. 2019 Aug;9(4):816-827
pubmed: 30924025
Pharm Res. 2003 Nov;20(11):1812-9
pubmed: 14661926
J Drug Target. 2011 May;19(4):239-50
pubmed: 20545446
Lipids Health Dis. 2012 Jun 13;11:72
pubmed: 22695222
AAPS PharmSciTech. 2017 Apr;18(3):875-883
pubmed: 27368922
J Nanobiotechnology. 2018 Sep 19;16(1):71
pubmed: 30231877
Colloids Surf B Biointerfaces. 2016 Mar 1;139:17-24
pubmed: 26700229
Antimicrob Agents Chemother. 2014 May;58(5):2608-13
pubmed: 24550333
Drugs. 2013 Nov;73(17):1863-88
pubmed: 24170666
Ther Adv Infect Dis. 2016 Jun;3(3-4):98-109
pubmed: 27536354
Pharm Res. 1997 Jul;14(7):923-9
pubmed: 9244151
J Microencapsul. 2010;27(1):78-85
pubmed: 19538034
AAPS PharmSciTech. 2007 Oct 12;8(4):E83
pubmed: 18181544
Pharm Res. 2015 Oct;32(10):3282-92
pubmed: 25968624
Emerg Infect Dis. 2012 Oct;18(10):1662-4
pubmed: 23017164
Eur J Pharm Sci. 2018 Mar 1;114:103-113
pubmed: 29229273
AAPS J. 2010 Sep;12(3):397-406
pubmed: 20458565
Food Funct. 2013 Sep;4(9):1410-9
pubmed: 23921424
Nanoscale Res Lett. 2016 Dec;11(1):524
pubmed: 27888498
Appl Biochem Biotechnol. 2014 Oct;174(4):1309-1330
pubmed: 25106894
PLoS Negl Trop Dis. 2017 Dec 14;11(12):e0006052
pubmed: 29240765
AAPS PharmSciTech. 2011 Mar;12(1):192-200
pubmed: 21194014
Int J Pharm. 2003 Jul 24;260(2):167-73
pubmed: 12842337
AAPS PharmSciTech. 2019 Mar 5;20(3):136
pubmed: 30838459
BMC Infect Dis. 2019 Aug 27;19(1):747
pubmed: 31455227
Infect Dis Poverty. 2016 Mar 08;5:19
pubmed: 26951132
Sci Rep. 2017 Jan 23;7:41322
pubmed: 28112262
Colloids Surf B Biointerfaces. 2011 Jul 1;85(2):145-52
pubmed: 21440424
Drug Deliv Transl Res. 2013 Oct;3(5):402-8
pubmed: 25788348
J Parasit Dis. 2019 Jun;43(2):176-185
pubmed: 31263321

Auteurs

Shabi Parvez (S)

Infectious Disease Biology Laboratory, Institute of Nano Science & Technology, Mohali, India.

Ganesh Yadagiri (G)

Infectious Disease Biology Laboratory, Institute of Nano Science & Technology, Mohali, India.

Archana Karole (A)

Infectious Disease Biology Laboratory, Institute of Nano Science & Technology, Mohali, India.

Om Prakash Singh (OP)

Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, India.

Anurag Verma (A)

School of Pharmaceutical Sciences, Institute of Foreign Trade and Management (IFTM) University, Moradabad, India.
Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University (TMU), Moradabad, India.

Shyam Sundar (S)

Infectious Disease Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.

Shyam Lal Mudavath (SL)

Infectious Disease Biology Laboratory, Institute of Nano Science & Technology, Mohali, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH